Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes
100% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
FREE – $17
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your montelukast sodium prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
For breathing problems:
This medicine may interact with other drugs or health problems.
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine (montelukast tablets) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
For all uses of this medicine (montelukast tablets):
For breathing problems:
Use this medicine (montelukast tablets) as ordered by your doctor. Read all information given to you. Follow all instructions closely.
What do I do if I miss a dose?
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
For all patients taking this medicine (montelukast tablets):
Children:
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Other brands: Singulair
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Montelukast Sodium (www.drugs.com/montelukast.html).
Applies to montelukast: oral packet, oral tablet, oral tablet chewable
Along with its needed effects, montelukast may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking montelukast:
Less common
Rare
Incidence not known
Some side effects of montelukast may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Incidence not known
Applies to montelukast: oral granule, oral tablet, oral tablet chewable
The most common adverse reactions (incidence more than 5% and greater than placebo) were: Upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis.
Very rare (less than 0.01%): Churg-Strauss Syndrome
Churg-Strauss syndrome is a rare granulomatous eosinophilic condition that involves the upper and lower airways and manifests as rhinitis, sinusitis and asthma. If untreated the syndrome may progress to systemic vasculitis, peripheral neuropathy and potentially fatal cardiac complications. In most cases, the condition emerged during withdrawal of oral corticosteroid therapy. A causative role for leukotriene receptor antagonists has not been ruled out.
Very common (10% or more): Headache (18.4%)
Common (1% to 10%): Dizziness (1.9%)
Postmarketing reports: Disturbance in attention, irritability, memory impairment, tremor, drowsiness, paraesthesia/hypoesthesia, seizures
Common (1% to 10%): Rash (1.6%), atopic dermatitis, skin infection, eczema, urticaria
Postmarketing reports: Angioedema, bruising, erythema multiforme, erythema nodosum, pruritus, Stevens-Johnson syndrome/toxic epidermal necrolysis
Common (1% to 10%): Abdominal pain (2.9%), dyspepsia (2.1%), dental pain (1.7%), gastroenteritis (1.5%), nausea, diarrhea, dyspepsia, gastroenteritis, tooth infection
Common (1% to 10%): ALT increase (2.1%), AST increased (1.6%)
Postmarketing reports: Hepatic eosinophilic infiltration; cases of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury. Most of these occurred in combination with other confounding factors, such as use of other medications, or when administered to patients who had underlying potential for liver disease such as alcohol use or other forms of hepatitis.
Common (1% to 10%): Myopia, conjunctivitis
Common (1% to 10%): Asthenia, fatigue (1.8%), fever (1.5%), trauma (1%), influenza, fever, otitis, viral infection, varicella, ear pain, otitis media
Uncommon (0.1% to 1%): Malaise
Postmarketing reports: Edema
Common (1% to 10%): Influenza (4.2%), cough (2.7%), nasal congestion (1.6%), pharyngitis, sinusitis, laryngitis, infective rhinitis, acute bronchitis, rhinorrhea, pneumonia, upper respiratory infection, wheezing, tonsillitis
Postmarketing reports: Epistaxis, pulmonary eosinophilia
Postmarketing reports: Palpitations
Postmarketing reports: Enuresis in children
Postmarketing reports: Increased bleeding tendency, thrombocytopenia
Postmarketing reports: Anaphylaxis
Postmarketing reports: Arthralgia, myalgia including muscle cramps
Postmarketing reports: Agitation including aggressive behavior or hostility, anxiousness, depression, disorientation, dream abnormalities, hallucinations, insomnia, restlessness, somnambulism, suicidal thinking and behavior (including suicide)
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Montelukast Sodium (www.drugs.com/montelukast.html).
August 6, 2020
August 6, 2020
August 6, 2020
August 6, 2020
August 6, 2020
August 6, 2020
